Clinical application of serum tumor abnormal protein in prostate cancer patients.

PURPOSE: To explore the clinical value of tumor abnormal protein (TAP) in the diagnosis and prognosis evaluation of prostate cancer. METHODS: This study enrolled a total of 265 patients who underwent prostate biopsy procedures from December 2017. TAP levels were assayed in their blood samples using a validated TAP testing kit. Comprehensive pathological assessments, including Gleason scores, TNM staging, and AJCC prognosis stages, were conducted on prostate cancer patients. Further analysis was carried out to examine the correlation between TAP expression levels and various clinical characteristics. RESULTS: A significantly elevated TAP concentration was discerned in prostate cancer patients relative to those with benign prostate hyperplasia. Moreover, a significantly elevated TAP expression was detected in prostate cancer patients with high Gleason score (≥ 8) and advanced stages (III and IV), as compared to those with Gleason scores of 6 and 7 and lower stages (I and II). When diagnosing prostate cancer in gray area of PSA, TAP demonstrated superior diagnostic capabilities over PSA alone, with higher diagnostic sensitivity, specificity and accuracy than fPSA/tPSA ratio. Additionally, post-surgical or hormonal treatment, there was a marked reduction in TAP expression level among prostate cancer patients. CONCLUSION: The assessment of TAP presents itself as a promising tool for early diagnosis and holds potential for sensitivity in monitoring treatment reponse in prostate cancer patients.

Tumor abnormal protein as a promising biomarker for screening solid malignancies and monitoring recurrence and metastasis.

Background: Tumor abnormal protein (TAP), the sugar chain protein released by tumor cells during metabolism, allows the development of a technique that exploits aggregated tumor-associated abnormal sugar chain signals in diagnosing malignancies. Clinically, we have found that TAP detection can well predict some malignancies, but several physicians have not paid attention, and related studies have been minimal. Methods: We evaluated TAP's ability to distinguish between malignancies and benign diseases by receiver operating characteristic (ROC) curve analysis and studied the possibility of monitoring malignancy progression by evaluating TAP levels in follow-up. We used Kaplan-Meier survival curves and Cox proportional hazard regression models to investigate the relationship between TAP and prognosis. Results: TAP levels were higher in whole solid malignancies and every type of solid malignancy than in benign patients. ROC curve analysis showed that TAP levels aid in distinguishing between malignancies and benign diseases. TAP levels decreased in patients with complete remission (CR) after treatment and increased in patients with relapse from CR. Patients with metastases had higher TAP levels than non-CR patients without metastases. There was no difference in overall survival among patients with different TAP levels, and multivariate analysis suggested that TAP was not an independent risk factor for solid malignancies. Conclusion: TAP is an effective screening biomarker for many solid malignancies that can be used to monitor the progression of malignancies but not to prognosticate.

Clinical significance of tumor abnormal protein in patients with type 2 diabetes complicated with lung adenocarcinoma in situ.

BACKGROUND: To investigate the application value of tumor abnormal protein in patients with type 2 diabetes mellitus complicated with lung adenocarcinoma in situ. MATERIALS AND METHODS: A total of 140 patients having type 2 diabetes mellitus complicated with lung adenocarcinoma in situ (Group A), 160 patients with type 2 diabetes mellitus (Group B), and 120 healthy controls (Group C) were enrolled in the Department of Thoracic Surgery of the First Affiliated Hospital of Soochow University from November 2021 to December 2022. RESULTS: The total cholesterol level was higher in Group A than in Group B (p < 0.05) and Group C (p < 0.01), and it was higher in Group B than in Group C (p < 0.01). The comparison results of cholesterol level were similar to those of tumor abnormal protein, low-density lipoprotein cholesterol, and glycosylated hemoglobin among the three groups. The triglyceride level was higher in Group A than in Group B and Group C (both p < 0.01). Group A had a higher level of high-density lipoprotein cholesterol than Group C (p < 0.01). The fasting plasma glucose level was higher in Group A than in Group B and Group C (both, p < 0.01). These findings indicated that tumor abnormal protein, glycosylated hemoglobin, high-density lipoprotein cholesterol, and fasting plasma glucose were independent factors for patients having type 2 diabetes mellitus complicated with lung adenocarcinoma in situ. CONCLUSION: Therefore, detecting tumor abnormal protein levels may help diagnose lung adenocarcinoma in situ in patients with type 2 diabetes mellitus.

The study found that tumor abnormal protein, glycosylated hemoglobin, high-density lipoprotein cholesterol, and fasting plasma glucose were independent factors for patients having type 2 diabetes mellitus complicated with lung adenocarcinoma in situ. Detecting tumor abnormal protein levels may help diagnose lung adenocarcinoma in situ in patients with type 2 diabetes mellitus.

Quantification of Tumor Abnormal Proteins in the Diagnosis and Postoperative Prognostic Evaluation of Gastric Cancer.

Background: Abnormal glycosylation of proteins has been identified in almost all types of cancers and is closely related to the cancer progression, metastasis, and survival of cancer patients. This study was to explore the values of serum tumor abnormal protein (TAP), an abnormal glycochain protein, in the diagnosis and prognosis of gastric cancer (GC). Methods: A total of 335 GC patients were included as the study group, and another 335 subjects served as the control group. Tumor abnormal protein expression was compared between the 2 groups. Correlation analysis was used to assess the correlations of TAP with clinicopathological factors. Gastric cancer patients were divided into training set and test set at a ratio of 2:1. Univariate and multivariate Cox regression analyses in training set were used to evaluate the prognostic significance of TAP in GC patients and explore the independent risk factors for overall survival (OS) and disease-free survival (DFS) to establish a prognostic model, followed by testing of the model. According to the median of TAP, 335 GC patients were divided into 2 groups to plot the survival curves of OS and DFS. Results: Tumor abnormal protein expression in the study group was significantly higher than in the control group. Taking the best cut-off value of TAP (110.128 µm2) as the diagnostic criteria for GC, the sensitivity and specificity of TAP were 83.58% and 97.61%, respectively, and the area under the receiver operating characteristics (ROC) curve was 0.935, which was not inferior to computed tomography (CT). Tumor abnormal protein expression was an independent risk factor for OS and DFS. The prognostic predictive value of TAP was better than that of pathological stage in GC patients. The model with TAP was effective in predicting prognosis. Conclusion: Tumor abnormal protein is an effective indicator for early screening and prognostic evaluation of GC and can also assist the clinical diagnosis and treatment of GC.

Clinical application of serum tumor abnormal protein combined with tumor markers in lung cancer patients.

Aim: To explore the clinical application of tumor abnormal protein (TAP) combined with tumor markers in the diagnosis of lung cancer. Methods: Samples from 248 lung cancer patients and 59 patients with benign lung diseases were tested for TAP and tumor markers pro-gastrin-releasing peptide, carcinoembryonic antigen, NSE, CYFRA 21-1 and CA72-4. Results: The sensitivity of TAP and CYFRA 21-1 in the lung cancer group was significantly higher than that of the other indexes. TAP combined with NSE and CYFRA 21-1 or combined with NSE, CYFRA 21-1 and squamous cell carcinoma antigen detection could reduce detection indicators under the premise it does not reduce the sensitivity and accuracy of lung cancer diagnosis, and at the same time could improve the specificity, positive predictive value and positive likelihood ratio of detection. Conclusion: TAP detection represents a promising diagnostic tool. It is also suggested that combination with established tumor markers and comprehensive judgment could improve the accuracy of lung cancer auxiliary diagnosis.

The presence of tumor abnormal protein (TAP) is closely related to the development and progression of many cancers. During metabolism, cancer cells can release complicated abnormal glycoproteins as well as calcium histone proteins which constitute TAP. In essence, TAP results from the glycosylation changes related to cancer cells. In this study, TAP and tumor markers were assessed for their diagnostic value in lung cancer. The serum levels of TAP, pro-gastrin-releasing peptide, carcinoembryonic antigen, CYFRA 21-1 and CA72-4 in the patients with lung cancer were significantly higher than in those with benign lung diseases. TAP combined with CYFRA 21-1 and CA72-4 or with CYFRA 21-1, CA72-4 and squamous cell carcinoma antigen could further improve the sensitivity of lung cancer diagnosis and is suitable for lung cancer screening in both normal and high-risk populations.

Preoperative tumor abnormal protein is a promising biomarker for predicting hepatocellular carcinoma oncological outcome following curative resection.

Introduction and Objectives: The objective of this study was to explore the potential relationship between tumor abnormal protein (TAP) and the prognosis of hepatocellular carcinoma (HCC) after a radical hepatectomy. Patients or Materials and Methods: This retrospective study included 168 HCC patients (tumor recurrence in 78 patients) who underwent a curative resection from January 2018 to June 2020. The whole population was categorized into a TAP high (≥224.6 µm2) or a TAP low group (<224.6 µm2). Results: There was no correlation between maximum tumor size and TAP. In the whole population or subgroups stratified by maximum tumor size, the recurrence-free survival (RFS) rate of the TAP low group was significantly higher than TAP high group (P < 0.05 for all). The multivariate analysis revealed that TAP (hazard ratio [HR], 3.47; 95% confidence interval [CI], 2.18-5.51; P < 0.001), large tumor size (HR, 2.18; 95% CI, 1.36-3.49; P < 0.001), poor tumor differentiation (HR, 0.53; 95% CI, 0.33-0.84; P = 0.007), and presence of microvascular invasion (MVI) (HR, 2.03; 95% CI, 1.28-3.22; P = 0.003) were independently associated with RFS. The prognostic implication of the nomogram incorporating TAP, maximum tumor diameter, tumor differentiation, and MVI was stronger than the model without TAP. Conclusion: The present study suggests that higher preoperative TAP is correlated with undesirable prognosis in HCC patients who underwent a radical hepatectomy. Our study provides a robust nomogram for RFS of postoperative HCC patients.

High Expression of Tumor Abnormal Protein Preoperatively Predicts Poor Prognosis of Patients With Esophageal Squamous Cell Carcinoma.

Background: Esophageal squamous cell carcinoma (ESCC) acts as a fatal malignant tumor among human beings and is marked by late-stage diagnosis, frequent recurrence, metastasis, and therapy resistance. Tumor abnormal protein (TAP) remarkably affects cancer development and progression of human cancers. TAP has been shown to be a biomarker for gastric and lung cancer progression. Nevertheless, the clinical value exhibited by TAP for ESCC has not been well-explained in the current literature. Methods: The present study included 183 ESCC cases who received surgical resection and 183 cases who had normal physical checkup from March 2013 to January 2015 at the People's Hospital of Chizhou, and used the TAP detection agent for evaluating the TAP relative level. Results: As found, ESCC patients presented an obviously higher TAP expression relative to cases who had normal physical checkup. Moreover, TAP expression was significantly downregulated after surgery. Furthermore, the TAP expression was correlated with gender, smoking, pathologic differentiation, and pN stage, but not with age, tumor location, surgical type, pT stage, and vascular invasion. High expression of TAP was significantly correlated with poorer overall survival (OS) rate in ESCC patients. TAP was an independent prognostic predictor in ESCC patients, based on the multivariate survival analysis. Conclusion: The study reveals how TAP upregulation promotes ESCC malignant progression, and concludes that TAP acts as the therapeutic target and potential biomarker specific to ESCC.

Early Study of Tumor Abnormal Protein in Gastric Adenocarcinoma.

OBJECTIVE: To study the correlation between tumor abnormal protein (TAP) and tumor markers, blood glucose, uric acid and coagulation function in gastric adenocarcinoma and to evaluate the clinical application of TAP in the diagnosis of gastric adenocarcinoma. METHODS: A total of 34 nontumor patients and 95 gastric adenocarcinoma patients admitted to the First Affiliated Hospital of Jinzhou Medical University were enrolled in this study. Fresh blood from patients' fingertips was collected, all blood samples were examined with TAP testing kit, and then searched and measured the condensed particulate matter. RESULTS: The comparison of TAP between nontumor patients and gastric adenocarcinoma patients was statistically significant (P<0.05). Bivariate correlation analysis was conducted between TAP and other related tumor markers (alpha-fetoprotein, carcinoembryonic antigen, carbohydrate antigen 19-9 (CA199), carbohydrate antigen 72-4 (CA72-4)), blood glucose, uric acid, and coagulation function-related indicators, and the results showed that the correlation between TAP and CA199, CA72-4, and activated partial prothrombin time was statistically significant. In addition, according to the analysis results, there was no significant difference among TAP and age, height and weight in the tumor population and the nontumor population. CONCLUSION: TAP can be used for the screening and diagnosis of gastric adenocarcinoma, and the effect of TAP combined with other indicators is more significant than TAP alone.

Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer.

BACKGROUND: The most common cancer among humans is lung cancer. Non-small cell lung cancer (NSCLC) comprises the majority of these cases. In the development and progression of cancers across the spectrum, tumor abnormal protein (TAP) plays crucial roles. Additionally, in the advancement of the bladder and colorectal cancers, the involvement of glycoproteins like TAP is present. However, it is worth noting that current literature has yet to clarify the clinical significance of the TAP in NSCLC. METHODS: In the present study, to evaluate the relative level of TAP, we utilized a TAP detection agent in 154 cases of NSCLC and normal patients who underwent surgical resection anytime from March 2013 to January 2019 at the People's Hospital of Chizhou. RESULTS: Our results demonstrated that in NSCLC patients, the expression level of TAP was significantly higher than in normal patients. Moreover, after surgery, TAP expression was significantly downregulated in NSCLC patients. TAP expression is associated with an array of factors, which include the patient's sex, history of smoking use, tumor size, pTNM, distant cancer, metastasis of lymph nodes, invasive and aggressive indicator pleural invasion, and differentiation degree of NSCLC. Additionally, TAP has no association with the patient's age, history of drinking, location of the tumor, hypertension, and diabetes. In NSCLC patients, a poor overall survival rate within 5 years is significantly correlated with the increased TAP expression. For NSCLC patients, an independent prognostic factor is the TAP, which is confirmed using the multivariate survival analysis. CONCLUSION: In the malignant progression of NSCLC, our results demonstrate how the promoting role of the upregulated TAP expression takes place. Hence, a therapeutic aim for NSCLC and a potential biomarker for NSCLC progress is a TAP.

Tumor Abnormal Protein in the Diagnosis of Breast Cancer in Patients with a Palpable Mass.

BACKGROUND: Tumor abnormal protein (TAP) is now gradually applied for early detection of cancers. The aim of this study was to assess the performance of serum TAP in breast cancer patients with a palpable mass. METHODS: TAP from peripheral blood of 217 breast cancer patients and 222 with benign tumors patients were compared. The relationships between TAP value and clinical parameters of breast cancer patients were analyzed. Receiver operating characteristic curve was employed to identify the diagnostic value of TAP. RESULTS: Higher TAP level was found in breast cancer patients compared with benign patients (P<0.001). TAP was not associated with estrogen receptor, progestogen receptor, her-2 expression, tumor size, and pathological degree, but it was significantly associated with the age, lymph node metastasis, and TNM stage (P=0.023, 0.017, and 0.031, respectively). At a cut-off TAP value of 121 µm2, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 59.45%, 63.96%, 61.72%, 61.74%, and 61.73%, respectively. CONCLUSION: Serum TAP may be used as a biomarker in breast cancer diagnosis, but receiver operating characteristic curve indicates it may be limited by its sensitivity/specificity characteristics.

Expression and clinical significance of tumor abnormal protein in breast cancer / 中华内分泌外科杂志

Objective To explore the clinical application value of serum tumor abnormal protein (TAP)in early diagnosis of breast cancer.Methods The serum TAP level was determined in 53 hospitalized patients with breast cancer and 65 cases of normal physical examination population as the control group.We further compared the positive rate of TAP in the two groups and the expression level of TAP between different clinical pathological parameters in breast cancer group.Results There was no case of TAP positive in the control group,while the positive rate of TAP was as high as 83.02％ in breast cancer group.TAP positive rate of the patients with negative PR (100.00％) was significantly higher than that of PR positive patients (73.53％)(P=0.019).However there was no significant difference of TAP positive rate between patients with different ages,clinical stages,lymph node metastasis and the different expression of ER,C-erbB2 and Ki67.Conclusion It might be clinically valuable to use TAP expression level as a screening marker for breast cancer in combination with the breast cancer hormone PR.

A study of the application of TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer.

The aim of the study was to investigate the application of tumor abnormal protein (TAP) combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer. A total of 248 patients with suspected endometrial cancer who were admitted to the Gynecology Department of the Second People's Hospital of Liaocheng from September 2013 to September 2015 were selected and randomly divided into the control (n=124) and the observation group (n=124). The control group received conventional ultrasound examination, while the observation, underwent TAP combined with conventional ultrasound examination. Differences in the definite diagnostic results of the two diagnostic methods and curettage were compared, and the application of TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer was studied. Among 248 patients receiving hysteroscopy and diagnostic curettage examination, there were 75 patients with early-stage endometrial cancer, and 173 benign patients. The total diagnostic accordance rate of conventional ultrasound for endometrial lesions was 87.90% (n=218), and the accordance rate for early-stage endometrial carcinoma was 90.67% (n=68); the total diagnostic accordance rate of TAP combined with vaginal ultrasound for endometrial lesions was 94.35% (n=234), and for early-stage endometrial cancer was 94.67% (n=71); of TAP combined with conventional ultrasound for endometrial lesions and endometrial cancer were higher than those of simple conventional ultrasound (P<0.05). The area under the curve (AUC) of conventional ultrasound in the diagnosis of endometrial cancer was 0.754 [95% confidence interval (CI): 0.211-2.534]. The AUC of TAP combined with vaginal ultrasound in the diagnosis of endometrial cancer was 0.814 (95% CI: 0.517-0.932), and a comparison between the two groups was statistically significant (P=0.011). The accuracy rate of TAP combined with transvaginal ultrasound in the diagnosis of early-stage endometrial cancer is relatively high, and it is worthy promoting and applying in clinical practice.

Correlation between serum tumor abnormal protein expression and chemotherapeutic effect in patients with lung adenocarcinoma / 肿瘤研究与临床

Objective To investigate the correlation between serum tumor abnormal protein (TAP) a nd chemotherapeutic effect in patients with lung adenocarcinoma. Methods A prospective study was conducted on 90 patients with lung adenocarcinoma Liyuan Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology from May 2012 to April 2016. The patients were divided into adjuvant chemotherapy group (30 cases) and palliative chemotherapy group (60 cases) according to the different treatment regimen. The adjuvant chemotherapy group was treated with FOLFOX regimen for postoperative adjuvant chemotherapy. The palliative chemotherapy group was treated with pemetrexed. The t test was used to compare the expression levels of TAP in both groups. The χ2 test was used to compare the relationship among expression of TAP, the positive results of tumor markers and the efficacy of chemotherapy. Pearson correlation analysis was used to analyze the expression level of TAP and changes of tumor markers. Results There was no statistically significant difference in serum TAP between the two groups before palliative chemotherapy [area of TAP condensed matter were (230±80)μm2 and (206±50) μm2, t=1.487, P<0.05]. The serum TAP expression in both groups was 100％. There was no statistically significant difference in serum TAP area between adjuvant chemotherapy group and palliative chemotherapy group (46.7 ％ vs. 48.3％, χ2= 0.022, P> 0.05). There was no statistically significant difference between the two groups in positive expression of tumor markers CA125, CEA, CA19-9 and ALP (χ2 values were 4.02, 3.81, 4.01, 5.01, all P>0.05). In the two groups, the changes of serum TAP before and after chemotherapy had no relationship with age, gender, pathological differentiation degree and the number of transfer viscera (all P>0.05). The expression of serum TAP, CEA and CA19-9 after chemotherapy in palliative chemotherapy group were related to the efficacy of chemotherapy (χ2=6.62, 7.78, 8.62, all P<0.01). Pearson correlation analysis showed that the changes of serum TAP in palliative chemotherapy group had no relationship with tumor markers CA125, CEA, CA19-9 and ALP (r values were 0.42, 0.19, 0.09, 0.28, all P> 0.05). The serum TAP level of the adjuvant chemotherapy group was positively correlated with the level of tumor marker CA125 (r=0.51, P=0.02), with no correlation with the changes of CEA, CA19-9 and ALP levels (r values were 0.20, 0.24, 0.19, all P>0.05). Conclusion The detection of serum TAP level in patients with lung adenocarcinoma has good accuracy and high sensitivity, which indicates that the serum level of TAP in patients with lung adenocarcinoma before and after chemotherapy can be used as an index to evaluate the efficacy of chemotherapy and an independent detection of lung adenocarcinoma.

Values of SCCAg, TAP and CEA in evaluating the efficacy of neoadjuvant chemotherapy for cervical cancer / 国际肿瘤学杂志

Objective To investigate the values of squamous cell carcinoma antigen (SCCAg),tumor abnormal protein (TAP),carcinoembryonic antigen (CEA) in evaluating the efficacy of neoadjuvant chemotherapy for cervical cancer.Methods A total of 100 patients with cervical cancer treated by neoadjuvant chemotherapy were selected from September 2015 to September 2017 in our hospital,and 100 healthy persons were selected as the control group at the same time.The serum levels of SCCAg,TAP and CEA were detected and the relationships between the levels of SCCAg,TAP,CEA and the efficacy of neoadjuvant chemotherapy were analyzed.Results The serum levels of SCCAg [(4.95 ±0.65) μg/L vs.(0.22 ±0.04) μg/L],TAP [(175.21 ± 25.42) μm2 vs.(75.45 ± 9.98) μm2],CEA [(35.65 ± 4.23) ng/ml vs.(1.26 ± 0.34) ng/rnl] in patients with cervical cancer were significantly higher than those of control group,and the differences were statistically significant (t =75.382,P ＜ 0.001;t =62.215,P ＜ 0.001;t =55.452,P ＜ 0.001).Three months after neoadjuvant chemotherapy for 100 cervical cancer patients,complete remission (CR) was achieved in 6 cases (6.00％),partial remission (PR) in 50 cases (50.00％),stable disease (SD) in 26 cases (26.00％),and progression disease (PD) in 18 cases (18.00％).The SCCAg,TAP and CEA levels of patients with CR [(2.12 ± 0.32) μg/L vs.(4.90 ± 0.52) μg/L,(133.12 ± 14.22) μm2 vs.(175.12 ± 24.32) μm2,(10.34 ± 2.42) ng/ml vs.(38.21 ± 7.82) ng/ml] and PR after chemotherapy were significantly lower than those before chemotherapy [(3.22 ± 0.47) μg/L vs.(4.94 ± 0.53) μg/L,(145.22 ± 17.77) μm2 vs.(179.52 ± 25.53) μm2,(16.75 ± 3.02) ng/ml vs.(39.12 ± 7.92) ng/ml],and the differences were statistically significant (t =11.153,P ＜ 0.001;t =3.562,P =0.004;t =8.340,P ＜ 0.001;t =17.169,P ＜ 0.001;t =7.797,P ＜ 0.001;t =18.662,P ＜ 0.001).The above indicators of patients with PD after chemotherapy were significantly higher than those before chemotherapy [(7.21 ± 0.84) μg/Lvs.(5.06±0.57) μg/L,(213.21 ±29.64) μm2vs.(171.56±26.87) μm2,(46.64± 5.12) ng/ml vs.(35.75 ± 7.88) ng/ml],and the differences were statistically significant (t =8.986,P ＜ 0.001;t =4.417,P ＜0.001;t =4.917,P ＜0.001).The differences of the above indicators before and after chemotherapy in patients with SD were not statistically significant [(5.03 ± 0.57) μg/L vs.(4.97 ± 0.55) μg/L;(175.51 ± 23.37) μm2 vs.(176.27 ± 26.55) μm2;(35.26 ± 7.34) ng/ml vs.(37.04 ± 7.73) ng/ml;t =0.386,P=0.701;t=0.110,P=0.913;t=0.851,P=0.399].The results of receiver operating characteristic (ROC) curve analysis showed that the sensitivity,specificity and accuracy of SCCAg in evaluating the neoadjuvant chemotherapy for cervical cancer were 85.71％,81.82％,84.00％,those of TAP were 82.14％,77.27％,80.00％,those of CEA were 78.57％,77.27％,78.00％,and those of the combined detection were 96.43％,95.45％,96.00％.The sensitivity,specificity and accuracy of the combined detection were significantly higher than those of the three alone,and the differences were statistically significant (x2 =14.434,P＜0.001,x2 =15.421,P＜0.001,x2 =21.741,P＜0.001).Conclusion The serum levels of SCCAg,TAP and CEA in patients with cervical cancer are decreased after neoadjuvant chemotherapy.Their level changes can be used as important indicators to evaluate the efficacy of chemotherapy,and the combination of the three has better evaluation efficiency,which is worth for further clinical promotion.

Significance of Tumor Abnormal Protein in Peripheral Blood in the Therapeutic Monitoring of Non-Small Cell Lung Cancer / 现代检验医学杂志

Objective To observe the significance of tumor abnormal protein (TAP)in the therapeutic monitoring of non-small cell lung cancer (NSCLC).Methods Peripheral blood from 30 NSCLC patients were collected to make smears at the moment of pre-treatment,half a month,one month,3 months and 6 months after therapy.TAP was detected by coacervation method.The maximum area of condense was applied to estimate the level of TAP.Thirty healthy subj ects were chose as con-trol group.Results The positive rate of TAP in NSCLC patients was 86.67%,and 3.33% of healthy subjects were positive in TAP.The difference was statistically significant (χ2=140.3,P<0.01).The condense area of TAP in patients withⅢ~Ⅳ stage of NSCLC [411(89,562)mm2]was significantly higher than those withⅠ~Ⅱ stage NSCLC [267(31,407)mm2]. The condense areas in both of two groups went down after treatment.A significant difference of condense area appeared inⅠ~Ⅱ stage of NSCLC patients a month after therapy as well as Ⅲ~Ⅳ stage of NSCLC patients half a month after treat-ment.The condense areas went to their lowest level 3 months after therapy.ForⅠ~Ⅱ stage patients,the condense area fell to 21% compared to that before treatment,but for patients withⅢ~Ⅳ stage of NSCLC,37% of pre-treatment condense ar-ea were detected.TheⅠ~Ⅱ stage of NSCLC patients had a greater decrease in condense area of TAP than theⅢ~Ⅳ stage patients by 3 months after treatment (χ2=6.22,P<0.05).Conclusion Detection of TAP in peripheral blood had a high sensitivity for NSCLC,and is able to monitoring the treatment effect.

Expression and clinical significance of TAP in lung cancer patients / 实用医学杂志

Objective To investigate the expression and clinical significance of tumor abnormal protein (TAP)in patients with lung cancer.Methods Plasma TAP concentration was measured by enzyme-linked immu-nosorbent assay(ELISA)in 93 patients with lung cancer and 100 healthy subjects.Results The plasma TAP con-centration[(187.71 ± 82.295)μm2]in lung cancer group was significantly higher than that in the healthy control group[(67.836 ± 28.642)μm2,t=13.991,P<0.05).The sensitivity of TAP in lung cancer group was 83.87%. Conclusions TAP can improve the early diagnosis rate of lung cancer patients,which is important for early diag-nosis and early treatment. TAP detection is suitable for lung cancer screening in healthy people and people with high risks.

Prognostic value of serum tumor abnormal protein in gastric cancer patients.

Aberrant glycosylation of protein occurs in nearly all types of cancers and has been confirmed to be associated with tumor progression, metastasis and the survival rate of patients. The present study aimed to explore the prognostic value of tumor abnormal protein (TAP) in gastric cancer patients. TAP was detected in the blood of 42 gastric cancer patients and 56 healthy volunteers by using the TAP testing kit. Univariate and multivariate Cox regression analysis were performed to evaluate the prognostic value of TAP. In total, 64.3% of gastric cancer patients were positive for TAP, and TAP was significantly correlated with poor prognosis [progression-free survival (PFS), 4.2 vs. 12.6 months; P=0.043]. TAP [hazard ratio (HR), 64.487; P<0.01), differentiation (HR, 17.279; P<0.01) and TNM stage (HR, 45.480; P<0.01) were found to be independent predictive factors for PFS. Furthermore, Kaplan-Meier curves indicated that TAP is associated with a reduced PFS in gastric cancer patients. The results of the present study therefore indicated that the TAP test has significant prognostic value for gastric cancer patients.

Tumor abnormal protein (TAP) examination contributes to primary diagnosis of bladder cancer.

OBJECTIVE: This study aims to investigate the application value of tumor abnormal protein (TAP) examination in the diagnosis of urothelial carcinoma of the bladder. METHOD: Abnormal sugar chain glycoproteins in the peripheral blood of 87 patients with urothelial carcinoma of the bladder were detected, and compared with non-tumor patients accompanied by hematuria. RESULT: TAP examination showed that the positive rate of the abnormal sugar chain glycoprotein in the peripheral blood of the 87 patients with urothelial carcinoma of the bladder was 78.16%, whereas that of the non-tumor patients was 10.81%. The former is significantly higher than the latter (P<0.01). CONCLUSION: TAP examination can be used to detect urothelial carcinoma of the bladder, and would be helpful in the diagnosis of urothelial carcinoma of the bladder by combining the clinical signs and symptoms.

The si gnificances tumor abnormal p rotein detection for diagnosis and prediction of prognosis in gastroin-tetsinal tumors / 实用肿瘤学杂志

Objective To investigate the possibility of tumor abnormal protein ( TAP) ,as index of diag-nosis and prediction of prognosis in gastrointestinal tumors (GITs).Methods The outpatients and inpatients as well as healthy physical examinees in our hospital were chosen as objects in the present study .The patients were divided into GIT group(120 cases),high-risk GIT group(123 cases)and normal group(117 cases).TAP ex-pression was detected in three groups.These study objects were followed up for one and a half years .Then the re-lationship between TAP expression and the occurrence or recurrence of tumors was analyzed .Rseults There were significant differences(P<0.001)among the three groups on the positive TAP with critical expression rate .TAP detections to GITs diagnosis sensitivity ,specificity ,positive predictive value ,negative predictive value and Youden index were 88.33%,85.83%,75.71%,93.64% and 0.74 respectively.TAP positive non GITs crowd tumori-genesis proportion (23.53%)was significantly higher than that of TAP -negative(0.49%)(P<0.001).GITs TAP positive patients relapse rate(33.33%)was significantly higher than negative ones (6.90%)(P<0.001). Conlcusion TAP can be an index for diagnosis ,early prevention ,monitoring of treatment effect and prediction of prognosis of gastrointestinal tumor .